The amyloid cascade hypothesis has been the dominant paradigm for drug discovery for AD, but recent advances in the understanding of tau biology in neurodegenerative diseases and difficulties of amyloid-directed immunotherapeutics have heightened interest in tau as a target for drug discovery [2–7], particularly tau oligomers [8, 9]. The gene discussed is MAPT; the disease is Alzheimer disease.